ClinicalTrials.gg

Program

tradipitant

Also written as “Tradipitant”, “VLY-686” and “LY686017”.

Its studies are mostly in Motion Sickness · Gastroparesis · Dermatitis, Atopic · Pruritus · Nausea, led by 2 companies.

Furthest: phase 3, since Jun 13, 201819 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals173 open or runningphase 3since Jun 13, 2018Aug 2, 2013Dec 1, 2026phase 3 · NCT07446439
Eli Lilly20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead

Also a collaborator on its studies: cross-research-s-a.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Sep 12, 2005.

  1. Nov 17, 2015Phase 1 study in Healthy VolunteersVanda Pharmaceuticals · NCT02621385 · 24 enrolled · Switzerland
  2. Jan 6, 2016Phase 2 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT02651714 · 168 enrolled · United States
  3. Nov 15, 2016Phase 2 study in GastroparesisVanda Pharmaceuticals · NCT02970968 · 152 enrolled · United States
  4. Jun 13, 2018Phase 3 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT03568331 · 375 enrolled · United States
  5. Nov 28, 2018Phase 2 study in Motion SicknessVanda Pharmaceuticals · NCT03772340 · 126 enrolled · United States
  6. Jul 10, 2019Phase 3 study in GastroparesisVanda Pharmaceuticals · NCT04028492 · 979 enrolled · United States
  7. Oct 24, 2019Phase 3 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT04140695 · 87 enrolled · United States
  8. Mar 26, 20202 phase 3 studiesVanda Pharmaceuticals · NCT04327661, NCT04326426
  9. Apr 13, 2021Phase 2 study in Healthy VolunteerVanda Pharmaceuticals · NCT04849559 · 27 enrolled · United States
  10. Mar 3, 2023Phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT06138613 · 705 enrolled · United States
  11. Jun 5, 2023Phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT05903924 · 316 enrolled · United States
  12. Apr 1, 2024Phase 3 study in GastroparesisVanda Pharmaceuticals · NCT06836557 · 17 enrolled · Belgium, Germany
  13. Jan 9, 2025Phase 2 study in ObesityVanda Pharmaceuticals · NCT06804603 · 124 enrolled · United States
  14. Feb 10, 2026Phase 3 study in NauseaVanda Pharmaceuticals · NCT07446439 · 280 planned · United States

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in NauseaVanda Pharmaceuticals · NCT07446439
  2. Sep 30, 2027Primary completion: phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT06138613

TargetBeta

TACR1 →read by rule
“An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
AprepitantruleMerckphase 427
elinzanetantruleBayerphase 324
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07446439Nausea · United States3RecruitingVanda PharmaceuticalsDec 1, 2026280
NCT06804603Obesity · United States2CompletedVanda PharmaceuticalsOct 6, 2025124
NCT06836557Gastroparesis · Belgium, Germany3CompletedVanda PharmaceuticalsMar 30, 202617
NCT05903924Motion Sickness · United States3CompletedVanda PharmaceuticalsApr 6, 2024316
NCT06138613Motion Sickness · United States3Active, not recruitingVanda PharmaceuticalsSep 30, 2027705
NCT04849559Healthy Volunteer · United States2CompletedVanda PharmaceuticalsSep 24, 202127
NCT04327661Motion Sickness · United States3CompletedVanda PharmaceuticalsApr 1, 2023366
NCT04326426Coronavirus Infections · United States3By invitationVanda PharmaceuticalsAug 1, 2020300
NCT04140695Dermatitis, Atopic · United States3TerminatedVanda PharmaceuticalsOct 14, 202087
NCT04028492Gastroparesis · United States3CompletedVanda PharmaceuticalsFeb 21, 2025979
NCT03772340Motion Sickness · United States2CompletedVanda PharmaceuticalsJun 6, 2019126
NCT03568331Dermatitis, Atopic · United States3CompletedVanda PharmaceuticalsDec 27, 2019375
NCT02970968Gastroparesis · United States2CompletedVanda PharmaceuticalsNov 2018152
NCT02651714Dermatitis, Atopic · United States2CompletedVanda PharmaceuticalsAug 4, 2017168
NCT02621385Healthy Volunteers · Switzerland1CompletedVanda PharmaceuticalsFeb 201624
NCT02004041Pruritus · Germany2CompletedVanda PharmaceuticalsFeb 19, 201569
NCT01919944Pruritus · Switzerland1CompletedVanda PharmaceuticalsNov 201312
NCT00805441Alcoholism · United States2CompletedEli LillyJul 2009190
NCT00191022Phobia, Social · United States2CompletedEli Lilly185

How it is read

Names in the registry

  • “Tradipitant”, 13 entries
  • “VLY-686”, 2 entries
  • “LY686017”, 2 entries
  • “Open Label Tradipitant”, 1 entry
  • “VLY-686 (Tradipitant)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.